https://www.biopharm.org.tw
+886-2-2655-8135
services@biopharm.org.twServices / Pipelines & Platforms
The Universal Antibody Lock Technology uses Hinge + Linker structure to prevent antibody binding to healthy tissues. The Linker, optimized through computational modeling, enables tumor-specific protease activation within the tumor microenvironment, minimizing toxicity while enhancing efficacy. ▪ Human Hinge Structure – Low immunogenicity, reducing autoimmune reactions and ADA formation ▪ Optimized Linker Design – Tumor-specific cleavage sites achieve the highest activation rate in TME ▪ Third-Party Validation – Validated by GlycoNex Inc. and licensed to GlycoNex Inc. on May 2024.
Key Pipeline ▪ PSM101 (Lock-EGFR) – Completed efficacy, safety, and process development ▪ PSM915 (Lock-TNFα) – Demonstrated RA disease inhibition with improved safety. Collaboration ▪ Contract Research – Lock-antibody design, production, validation. ▪ Technology Licensing – Universal Antibody Lock IP transfer. ▪ Technology Licensing – Universal Antibody Lock IP transfer. ▪ Product Licensing – Lock-anti-PD1, CTLA-4, CD28, CD47, CD3, IL-1β, 4-1BB. ▪ Co-Promotion – CDMO partnerships for platform expansion. ▪ Direct Investment – Series A fundraising for strategic partners & investors.
Business Interests
Out-Licensing, Collaborative R&D, Clinical Trial Collaboration, Co-Development, Strategic Alliance
Contact Info
Bingtsung Wu
Business Development Manager
+886-7-311-1577
bingtsung.wu@precisemab.com